Childhood Kidney Diseases

  • 제27권2호
  • /
  • Pages.76-81
  • /
  • 2023
  • /
  • 2384-0242(pISSN)
  • /
  • 2384-0250(eISSN)
대한소아신장학회 (Korean Society of Pediatric Nephrology)
권호 표지
DOI QR코드

DOI QR Code

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?

  • Hee Sun Beak (Department of Pediatrics, Yeungnam University College of Medicine) ;
  • Min Hyun Cho (Department of Pediatrics, School of Medicine, Kyungpook National University)
  • 투고 : 2023.10.25
  • 심사 : 2023.12.01
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce cyst expansion in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is currently the preferred treatment of rapidly progressive disease ADPKD in adult patients; however, since cyst formation in ADPKD begins early in life, (frequently in utero), and significant disease progression with cyst expansion occurs in the first decade, tolvaptan may be advantageous as a preemptive treatment in children with ADPKD. Tolvaptan has already been used to successfully treat refractory edema or hyponatremia in children; this literature review provides insight into the biochemical basis of its action to contextualize its use in the pediatric population.

키워드

참고문헌

  1. Olesen ET, Fenton RA. Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases. Nat Rev Nephrol 2021;17:765-81. https://doi.org/10.1038/s41581-021-00447-x
  2. Torres VE. Role of vasopressin antagonists. Clin J Am Soc Nephrol 2008;3:1212-8. https://doi.org/10.2215/CJN.05281107
  3. Torres VE, Chapman AB, Desvuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18. https://doi.org/10.1056/NEJMoa1205511
  4. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017;377:1930-42. https://doi.org/10.1056/NEJMoa1710030
  5. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, et al. Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2020;16:48-58. https://doi.org/10.2215/CJN.10250620
  6. Torres VE, Gansevoort RT, Perrone RD, Chapman AB, Ouyang J, Lee J, et al. Tolvaptan in ADPKD patients with very low kidney function. Kidney Int Rep 2021;6:2171-8. https://doi.org/10.1016/j.ekir.2021.05.037
  7. Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, et al. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep 2022;7:1037-48. https://doi.org/10.1016/j.ekir.2022.02.009
  8. Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018;29:2458-70. https://doi.org/10.1681/ASN.2018060590
  9. Muller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant 2022;37:825-39. https://doi.org/10.1093/ndt/gfab312
  10. Gkekas E, Tang TY, Green A, Davidson H, Fraser R, Sayer JA, et al. Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan. Front Nephrol 2022;2:984165.
  11. Kataoka H, Shimada Y, Kimura T, Nishio S, Nakatani S, Mochizuki T, et al. Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2023;27:809-18. https://doi.org/10.1007/s10157-023-02372-8
  12. Gkika V, Louka M, Tsagkatakis M, Tsirpanlis G. The efficacy, the treatment response and the aquaretic effects of a three-year tolvaptan regimen in polycystic kidney disease patients. Clin Pract 2023;13:1035-42.
  13. Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol 2014;29:915-7. https://doi.org/10.1007/s00467-013-2687-1
  14. Marx-Berger D, Milford DV, Bandhakavi M, Van't Hoff W, Kleta R, Dattani M, et al. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants. Acta Paediatr 2016;105:e334-7. https://doi.org/10.1111/apa.13415
  15. Higashi K, Murakami T, Ishikawa Y, Itoi T, Ohuchi H, Kodama Y, et al. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). Int J Cardiol 2016;205:37-42. https://doi.org/10.1016/j.ijcard.2015.12.003
  16. Katayama Y, Ozawa T, Shiono N, Masuhara H, Fujii T, Watanabe Y. Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery. Gen Thorac Cardiovasc Surg 2017;65:622-6. https://doi.org/10.1007/s11748-017-0798-5
  17. Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P. Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion: a report of three cases. J Clin Res Pediatr Endocrinol 2017;9:288-92. https://doi.org/10.4274/jcrpe.4531
  18. Koksoy AY, Kurtul M, Ozsahin AK, Cayci FS, Tayfun M, Bayrakci US. Tolvaptan use to treat SIADH in a child. J Pediatr Pharmacol Ther 2018;23:494-8. https://doi.org/10.5863/1551-6776-23.6.494
  19. Kerling A, Toka O, Ruffer A, Muller H, Habash S, Weiss C, et al. First experience with tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery. BMC Pediatr 2019;19:57.
  20. Delbet JD, Parmentier C, Ulinski T. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. Pediatr Nephrol 2020;35:1347-50. https://doi.org/10.1007/s00467-020-04530-6
  21. Meena J, Hari P, Sinha A, Bagga A. Efficacy and safety of combination therapy with tolvaptan and furosemide in children with nephrotic syndrome and refractory edema: a prospective interventional study. Indian J Pediatr 2022;89:699-705. https://doi.org/10.1007/s12098-021-03988-y
  22. Piffer A, Bianchetti MG, Leoni-Foglia C, Simonetti GD, Milani GP, Lava SA. Vaptans for oedematous and hyponatraemic disorders in childhood: a systematic literature review. Br J Clin Pharmacol 2022;88:4474-80. https://doi.org/10.1111/bcp.15367
  23. Hartung EA. Tolvaptan for autosomal dominant polycystic kidney disease in children: why, who, and when? Clin J Am Soc Nephrol 2023;18:11-3. https://doi.org/10.2215/CJN.0000000000000028
  24. Gimpel C, Bergmann C, Mekahli D. The wind of change in the management of autosomal dominant polycystic kidney disease in childhood. Pediatr Nephrol 2022;37:473-87. https://doi.org/10.1007/s00467-021-04974-4
  25. De Rechter S, Breysem L, Mekahli D. Is autosomal dominant polycystic kidney disease becoming a pediatric disorder? Front Pediatr 2017;5:272.
  26. Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, et al. Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials. Am J Kidney Dis 2023;81:281-93. https://doi.org/10.1053/j.ajkd.2022.08.012
  27. Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D. Expanding the role of vasopressin antagonism in polycystic kidney diseases: from adults to children? Pediatr Nephrol 2018;33:395-408. https://doi.org/10.1007/s00467-017-3672-x
  28. Gilbert RD, Evans H, Olalekan K, Nagra A, Haq MR, Griffiths M. Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease. Pediatr Nephrol 2017;32:893-6. https://doi.org/10.1007/s00467-017-3584-9
  29. Raina R, Chakraborty R, DeCoy ME, Kline T. Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression. Pediatr Res 2021;89:894-9. https://doi.org/10.1038/s41390-020-0942-2
  30. Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, et al. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 2019;178:1013-21. https://doi.org/10.1007/s00431-019-03384-x
  31. Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, et al. Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial. Clin J Am Soc Nephrol 2023;18:36-46. https://doi.org/10.2215/CJN.0000000000000022
  32. Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol 2019;15:713-26. https://doi.org/10.1038/s41581-019-0155-2